This discussion examines the key considerations oncologists weigh when choosing between chemotherapy alone or chemotherapy ...
PD-1 checkpoint proteins on T cells (blue) can bind to two different receptors: PD-L1 and PD-L2. There are many ways to climb a mountain. This saying especially rings true in cancer research, where ...
Exploratory biomarker analysis for predicting treatment effects of aflibercept in the VELOUR trial. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include ...
The first CDE-designated Breakthrough Therapy for perioperative gastric cancer, promising accelerated patient access. The ...
DUBLIN--(BUSINESS WIRE)--The "PD-1 x VEGF and PD-L1 x VEGF Bispecific Antibodies: A Business, Pipeline And Competitor Analysis From An Industry Perspective" report has been added to ResearchAndMarkets ...
When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Merck & Co.’s cancer immunotherapy Keytruda is one of ...
A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation for why some cancer patients receiving a type of immunotherapy called checkpoint ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback